Empowering mental health care specialists with a first-of-its-kind diagnostic device, our technology diagnose and distinguishes mental health disorders with precision, identifying at-risk individuals and guiding treatment.
We are dedicated to tackling the mental health crisis head-on. With our innovative diagnostic device, we empower mental health care specialists to provide precise diagnoses and tailored treatments to patients.
The actual experience and timeline can vary significantly for each individual based on factors such as the severity of symptoms, access to healthcare, social support, and individual response to treatment. Early recognition of symptoms and prompt intervention can improve outcomes.
Individual costs touch on every aspect related to one’s quality of life, from loss of productivity, autonomy, finances, and time.
The overlap between individual costs and societal costs when a person experiences mental health issues is significant and multifaceted.
The psychosis diagnostics market is on a robust growth trajectory, evidenced by a jump from US$ 2.04 Billion in 2022 to a projected US$ 3.6 Billion by 2033, expanding at a CAGR of 5.3%.
Dedicated professionals, guides our journey with a focus on practical innovation in mental health diagnostics.
Co-Founder & CEO
Doctoral Candidate in Neuroscience - UDEM
Co-Founder & Vice-President
Psychiatry Resident CHUM
Co-Founder & COO
Former Vice-President PGSS McGill
The brilliant minds behind our pioneering diagnostic technologies, committed to advancing mental health care through science.
CEO - NeoVentures Biotechnology
Biosensor synthesis
Professor - Université de Montréal
Neuropsychiatry expert
Machine & Deep Learning
Biotechnology
Our Board Members and Advisers bring a wealth of expertise and experience from various industries, uniting as visionary leaders to guide our strategic direction.
Chairman of the Board
Former president of CIHR
Board Member
Co-founder and VP of AV & R